Erythrasma

L12_ERYTHRASMA

erythrasma: a skin disease that causes brown, scaly skin patches. It is caused by the Gram-positive bacterium Corynebacterium minutissimum. It is prevalent among diabetics and the obese, and in warm climates; it is worsened by wearing occlusive clothing.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — L08.1
  • Hospital discharge: ICD-9 — 390
  • Cause of death: ICD-10 — L08.1
  • Cause of death: ICD-9 — 390

2 out of 7 registries used, show all original rules.

93

4. Check minimum number of events

None

93

5. Include endpoints

None

93

6. Filter based on genotype QC (FinnGen only)

87

Control definitions (FinnGen only)

Control exclude
L12_INFECT_SKIN

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
L08
Name in latin
Erythrasma

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 476 191 281
Only index persons 408 160 248
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 50.66 50.13 50.99
Only index persons 47.94 47.52 48.22

-FinnGen-

Key figures

All Female Male
Number of individuals 87 28 59
Unadjusted period prevalence (%) 0.02 0.01 0.03
Median age at first event (years) 55.29 57.69 54.16

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
92
Matched controls
920
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L08.1
ICD-10 Finland
Erythrasma
+∞
111.4
83
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
5.4
13.7
38
106
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
4.6
11.3
39
127
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
8.7
9.7
21
30
3900A
ICD-9 Finland
Rheumatic fever without mention of heart involvement[FEBRIS RHEUMATICA, MORBO CORDIS NON INDICATO]
+∞
7.4
7
*
D07AC01
ATC
betamethasone; topical
3.1
6.7
45
216
D07AB02
ATC
hydrocortisone butyrate; topical
3.1
6.0
36
160

TimeCodeWAS

↥

TimeCodeWAS is a tool for exploring time-dependent associations between an endpoint and health codes (diagnoses, lab tests, procedures, etc.).

The TimeCodeWAS analysis is done in three steps:

  1. Build a matched case-control set for this endpoint. Each case is matched to 5–10 controls on sex and year of birth, and controls must be at risk at the same age as the case's age of onset. TimeCodeWAS allows for controls to be reused.
  2. Count cases and controls. For each health code, and for each time window: tally the counts into a 2×2 table. To be eligible in a time window, a case or control must have data coverage for at least 50% of that time window.
  3. Perform association tests. If all cells of the 2×2 table have N≥10, then a χ² test is performed, otherwise a Fisher's exact test is done. The corresponding p-value and confidence interval are reported below, along with the standard odds ratio when a χ² test is done, or Fisher's MLE odds ratio otherwise.

TimeCodeWAS currently uses the same default set of time windows for all the endpoints. Please reach out to us if you have suggestions for better time windows for some endpoints. The default time windows are: TimeCodeWAS time windows

Sort & Filter
Sort
Odds Ratio
among windows:
Filter
Code & OMOP
Cases and controls with code
in
Odds Ratio
in
OMOP Concept
Code (OMOP Vocabulary) [OMOP Concept ID]
OMOP Concept Class / OMOP Domain
Odds Ratio
TimeCodeWAS O.R. time legend
Cases and controls with code
TimeCodeWAS Cases and Controls percentages time legend
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X (NUCC) [38003841]
Physician Specialty / Provider
3.7e-01 2.2e+00 — 1.0e+50 3.8e+00 3.4e+00 1.6e+00
10.11%/7.19% 21.35%/3.03% —/— 83.15%/0.00% 20.22%/0.56% 40.00%/2.24% 23.61%/5.88%
Case Management Agency
251B00000X (NUCC) [38004193]
Visit / Visit
1.3e-01 3.8e-01 3.2e-01 3.4e+00 8.0e-01 3.3e-01 3.2e-01
56.18%/52.92% 56.18%/46.74% 26.97%/21.12% 33.71%/1.57% 37.08%/20.92% 56.47%/48.23% 66.67%/59.11%
Pharmacy visit
OMOP4822462 (Visit) [581458]
Visit / Visit
6.0e-01 1.1e+00 5.0e-01 3.3e+00 1.0e+00 7.2e-01 —
92.13%/86.52% 89.89%/74.61% 50.56%/38.31% 23.60%/1.12% 64.04%/38.81% 85.88%/74.76% —/—
Dermatitis, unspecified
L30.9 (ICD10) [45572271]
ICD10 code / Condition
1.2e+00 3.1e+00 — — — 2.8e+00 1.2e+00
5.62%/1.80% 11.24%/0.56% —/— —/— —/— 10.59%/0.71% 6.94%/2.30%
Supplier / Service Provider
OMOP5117446 (Visit) [33004]
Visit / Visit
-6.3e-01 — — — — — 3.0e+00
15.73%/25.96% —/— —/— —/— —/— —/— 15.28%/0.86%
terbinafine; oral
D01BA02 (ATC) [21601967]
ATC 5th / Drug
— 3.0e+00 — — — — —
—/— 10.11%/0.56% —/— —/— —/— —/— —/—
hydrocortisone
S02BA01 (ATC) [21605166]
ATC 5th / Drug
4.7e-01 2.5e+00 — — — 1.8e+00 1.3e+00
7.87%/5.06% 15.73%/1.57% —/— —/— —/— 7.06%/1.30% 19.44%/6.03%
imidazoles/triazoles in combination with corticosteroids
D01AC20 (ATC) [21601936]
ATC 5th / Drug
1.4e+00 2.4e+00 — 1.0e+50 — 1.9e+00 2.1e+00
12.36%/3.37% 13.48%/1.35% —/— 5.62%/0.00% —/— 8.24%/1.30% 25.00%/4.02%
betamethasone
S03BA03 (ATC) [21605203]
ATC 5th / Drug
— — — — — — 2.4e+00
—/— —/— —/— —/— —/— —/— 13.89%/1.43%

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
22
83
3.17
4.74
1.4
1.6
—
—
—
0
0
42
237
2.42
4.10
5.1
2.6
36.03
49.85
e6/l
0.18
37
180
13
32
4.55
4.10
1.1
1.1
—
—
—
0
0
28
132
2.61
3.99
1.1
1.3
35.17
14.28
u/ml
—
10
53
37
200
2.42
3.95
5.2
2.5
0.32
0.33
e6/l
0.02
32
141
61
425
2.29
3.45
12.2
9.9
3.90
4.06
e9/l
0.25
55
373
33
185
2.22
3.13
4.1
4.1
—
—
—
0
0
21
98
2.48
2.99
1.2
1.2
—
—
—
0
0
29
157
2.24
2.97
1.4
1.8
1.12
1.52
mg/l
0.37
20
131
51
344
2.08
2.97
10.8
7.6
1.21
1.21
mmol/l
0.37
46
304
52
354
2.08
2.95
8.5
6.0
2.77
2.86
%
0.13
52
337
56
392
2.10
2.94
8.0
6.1
0.62
0.57
e9/l
0.62
51
338
22
107
2.39
2.87
4.9
2.4
1.54
2.06
e6/l
0.16
13
50
52
357
2.05
2.85
8.6
6.0
9.02
8.78
%
0.25
52
341
51
352
2.01
2.71
8.5
6.0
0.67
0.69
%
0.07
51
334
42
271
2.01
2.69
6.0
3.2
19.26
161.54
e6/l
0.58
37
186
26
142
2.16
2.58
1.2
1.3
54.75
46.89
iu/ml
—
8
41
5
8
6.53
2.40
1.0
1.3
27.40
22.25
ng/l
—
5
8
8
23
3.71
2.33
1.9
1.7
1.07
1.22
g/l
—
8
23
15
67
2.48
2.32
6.5
4.2
7.39
7.39
ph
—
10
42
19
95
2.26
2.31
9.3
8.0
102.84
104.23
mmol/l
0.52
19
95
29
173
1.99
2.26
1.6
1.4
1.80
2.02
u/ml
—
7
52
27
157
2.02
2.25
1.8
1.4
3.24
2.58
g/l
0.55
18
102
38
249
1.90
2.25
5.8
6.1
—
—
—
0
0
16
75
2.37
2.24
1.3
1.7
—
—
—
0
0
21
111
2.16
2.24
1.3
1.4
546.67
375.00
titre
—
6
24
25
142
2.04
2.22
1.7
1.8
—
—
—
0
0
8
25
3.40
2.15
1.5
4.1
13.00
21.45
u/ml
—
8
20
13
58
2.45
2.02
8.8
9.6
—
—
—
0
0
7
22
3.36
1.92
2.0
1.6
0.21
0.26
g/l
—
7
22
21
118
2.01
1.90
1.9
1.8
—
—
—
0
0
5
12
4.34
1.85
1.0
1.5
—
—
—
0
0
29
186
1.82
1.78
8.0
4.8
—
—
—
0
0
10
40
2.68
1.73
1.2
1.3
—
—
—
0
0
10
42
2.55
1.68
1.7
2.5
—
—
—
0
0
15
79
2.07
1.60
1.7
1.8
—
—
—
0
0
73
625
1.81
1.49
25.4
17.7
13.74
13.57
%
0.42
73
616
7
28
2.62
1.48
1.1
1.0
—
—
—
0
0
6
22
2.84
1.46
5.8
5.0
—
—
—
0
0
40
297
1.61
1.40
2.2
1.9
93.98
93.23
pmol/l
0.04
29
170
16
91
1.92
1.40
3.8
3.1
4.46
7.23
e9/l
0.50
16
79
8
35
2.41
1.30
6.0
3.1
0.63
0.70
%
—
8
35
5
18
2.88
1.30
2.6
2.1
48.80
127.50
ug/min
—
5
11
8
36
2.34
1.28
6.0
3.0
1.20
1.49
%
—
8
36
11
57
2.06
1.23
8.3
4.3
0.20
0.13
%
—
5
16
31
224
1.58
1.19
5.0
6.0
—
—
—
0
0
37
279
1.55
1.18
4.4
3.3
24.60
62.80
ng/l
1.21
28
191
5
20
2.58
1.16
1.0
1.3
596.00
474.40
mg/l
—
5
20
17
105
1.76
1.16
1.5
1.4
—
—
—
0
0
12
66
1.94
1.15
1.7
1.8
12.77
10.66
g/l
0.46
12
61
11
61
1.91
1.03
1.5
1.2
—
—
—
0
0
40
315
1.48
1.01
10.9
6.7
1.21
1.21
mmol/l
0.42
40
303
17
110
1.67
0.99
5.0
2.3
2.40
2.33
g/l
0.16
17
101
30
225
1.49
0.95
5.0
3.6
84.25
80.44
mg/l
0.02
22
164
18
120
1.62
0.94
4.9
2.4
11.86
14.62
umol/l
0.81
18
113
42
338
1.45
0.93
18.6
12.8
1.16
1.24
inr
0.52
37
271
31
235
1.48
0.93
2.7
2.1
—
—
—
0
0
40
320
1.44
0.91
4.6
3.0
6.25
6.12
ph
0.33
28
179
11
64
1.82
0.91
10.3
3.7
0.33
1.20
%
—
6
25
41
330
1.44
0.91
5.1
3.0
—
—
—
0
0
62
540
1.45
0.88
4.9
3.9
14.66
14.63
pmol/l
0.03
57
501
23
166
1.51
0.87
5.2
2.8
—
—
—
0
0
23
167
1.50
0.84
2.0
2.1
—
—
—
0
0
40
330
1.38
0.74
3.2
2.6
—
—
estimate
—
0
0
47
399
1.36
0.72
4.7
3.4
0.00
0.00
estimate
—
10
76
30
238
1.39
0.69
7.2
4.1
14.10
12.18
mg/mmol
0.07
23
167
40
333
1.36
0.69
15.1
11.1
0.00
0.01
e9/l
0.50
34
262
48
412
1.35
0.67
5.1
3.5
0.00
0.00
estimate
—
10
71
29
230
1.38
0.67
4.3
2.6
—
0.29
—
0
7
47
405
1.33
0.63
5.2
3.4
0.00
0.00
estimate
—
10
76
5
30
1.70
0.62
1.0
1.2
—
—
—
0
0
79
740
1.48
0.58
22.3
14.4
19.71
22.75
mg/l
0.46
73
604
12
83
1.51
0.55
8.8
9.0
7.41
7.43
ph
—
7
43
12
83
1.51
0.55
8.8
9.0
13.91
12.02
kpa
0.39
12
77
12
83
1.51
0.55
8.8
9.0
5.51
5.02
kpa
0.46
12
77
29
237
1.33
0.55
4.7
3.1
0.00
0.00
estimate
—
9
63
6
39
1.58
0.54
2.8
5.1
4.12
4.82
pmol/l
—
6
31
5
33
1.54
0.42
1.0
1.2
—
—
—
0
0
5
33
1.54
0.42
1.0
1.2
—
—
—
0
0
5
33
1.54
0.42
1.0
1.2
—
—
—
0
0
5
33
1.54
0.42
1.0
1.2
—
—
—
0
0
5
34
1.50
0.41
2.8
1.2
—
—
—
0
0
5
35
1.45
0.40
1.2
1.4
—
—
—
0
0
25
212
1.25
0.35
1.3
1.4
—
—
—
0
0
33
289
1.22
0.35
2.0
1.9
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
—
—
0
0
7
58
1.22
0.18
7.9
3.6
—
—
—
0
0
7
58
1.22
0.18
4.3
4.3
7.33
7.30
ph
—
7
49
7
59
1.20
0.18
1.1
1.6
42.00
40.19
nmol/l
—
7
59
69
670
1.12
0.13
6.6
4.8
2.09
1.85
mu/l
0.89
64
625
34
319
1.10
0.13
5.0
3.4
0.00
0.03
estimate
—
7
66
11
95
1.18
0.12
1.7
1.5
—
—
—
0
0
77
754
1.13
0.10
26.3
16.3
3.96
3.99
mmol/l
0.50
77
741
10
87
1.17
0.10
1.3
1.3
—
—
—
0
0
77
755
1.12
0.09
26.1
16.3
139.95
139.79
mmol/l
0.22
77
745
5
47
1.07
0.09
3.6
5.8
—
—
—
0
0
75
764
0.90
0.08
7.2
5.6
2.71
2.71
mmol/l
0.01
70
721
10
88
1.15
0.08
1.7
1.4
—
—
—
0
0
79
779
1.10
0.06
20.3
13.1
—
—
—
0
0
12
110
1.10
0.05
1.9
1.8
—
—
—
0
0
21
221
0.94
0.05
3.6
3.0
0.55
0.73
ug/l
1.18
15
145
20
190
1.07
0.04
4.9
3.1
1.02
1.02
kg/l
1.55
14
113
71
719
0.95
0.03
6.4
4.9
6.28
5.94
mmol/l
0.90
66
673
22
219
1.01
0.00
4.6
3.6
0.00
0.00
estimate
—
10
66
7
69
1.02
-0.00
1.3
1.3
—
—
—
0
0
83
821
1.11
-0.00
34.6
21.7
90.24
90.84
fl
0.58
83
815
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
83
822
1.10
-0.00
34.5
21.6
30.11
30.38
pg
0.66
83
816
8
81
0.99
-0.00
1.5
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.1
—
73.38
—
0
8
83
822
1.10
-0.00
34.6
21.7
6.80
6.64
e9/l
0.29
83
808
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
0.00
—
0
5
7
78
0.89
-0.00
2.0
1.9
3.01
3.40
mmol/l
—
7
56
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
5.4
—
25.88
—
0
8
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
83
822
1.10
-0.00
35.6
22.1
41.38
41.55
%
0.14
83
816
0
6
0.00
-0.00
0.0
1.0
—
30.17
—
0
6
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
83
822
1.10
-0.00
35.0
21.8
138.46
139.87
g/l
0.40
83
817
83
822
1.10
-0.00
34.6
21.7
4.61
4.64
e12/l
0.16
83
808
0
5
0.00
-0.00
0.0
4.6
—
25.60
—
0
5
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint L12_ERYTHRASMA and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have L12_ERYTHRASMA.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: L12_ERYTHRASMA – Erythrasma

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data